Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
18
12
2019
revised:
05
05
2020
accepted:
08
05
2020
pubmed:
19
5
2020
medline:
23
12
2020
entrez:
19
5
2020
Statut:
ppublish
Résumé
To generate recommendations for long-term follow-up of adult survivors of heritable retinoblastoma. We convened a meeting of providers from retinoblastoma centers around the world to review the state of the science and to evaluate the published evidence. Retinoblastoma is a rare childhood cancer of the retina. Approximately 40% of retinoblastoma cases are heritable, resulting from a germline mutation in RB1. Dramatic improvements in treatment and supportive care have resulted in a growing adult survivor population. However, survivors of heritable retinoblastoma have a significantly increased risk of subsequent malignant neoplasms, particularly bone and soft tissue sarcomas, uterine leiomyosarcoma, melanomas, and radiotherapy-related central nervous system tumors, which are associated with excess morbidity and mortality. Despite these risks, no surveillance recommendations for this population currently are in place, and surveillance practices vary widely by center. Following the Institute of Medicine procedure for clinical practice guideline development, a PubMed, EMBASE, and Web of Science search was performed, resulting in 139 articles; after abstract and full-text review, 37 articles underwent detailed data abstraction to quantify risk and evidence regarding surveillance, if available. During an in-person meeting, evidence was presented and discussed, resulting in consensus recommendations. Diagnosis and mortality from subsequent neoplasm. Although evidence for risk of subsequent neoplasm, especially sarcoma and melanoma, was significant, evidence supporting routine testing of asymptomatic survivors was not identified. Skin examination for melanoma and prompt evaluation of signs and symptoms of head and neck disease were determined to be prudent. This review of the literature confirmed some of the common second cancers in retinoblastoma survivors but found little evidence for a benefit from currently available surveillance for these malignancies. Future research should incorporate international partners, patients, and family members.
Identifiants
pubmed: 32422154
pii: S0161-6420(20)30462-0
doi: 10.1016/j.ophtha.2020.05.024
pmc: PMC7606265
mid: NIHMS1596662
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1549-1557Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 American Academy of Ophthalmology. All rights reserved.
Références
JAMA Pediatr. 2017 Jul 1;171(7):705-707
pubmed: 28531274
Pediatr Blood Cancer. 2015 Oct;62(10):1799-804
pubmed: 25970657
JAMA. 1997 Oct 15;278(15):1262-7
pubmed: 9333268
Annu Rev Med. 2014;65:171-84
pubmed: 24422571
Cancer. 2014 Jan 1;120(1):126-33
pubmed: 24122173
Eur J Cancer. 2013 May;49(8):1939-47
pubmed: 23415887
Fam Cancer. 2017 Jul;16(3):423-432
pubmed: 28124295
J Am Acad Dermatol. 2016 Mar;74(3):395-407; quiz 408-10
pubmed: 26892650
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):224-33
pubmed: 23102695
J Natl Cancer Inst. 2009 Apr 15;101(8):581-91
pubmed: 19351917
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8
pubmed: 22710039
Jpn J Clin Oncol. 2015 Dec;45(12):1139-45
pubmed: 26438540
Curr Opin Ophthalmol. 2016 Sep;27(5):443-8
pubmed: 27213925
Br J Ophthalmol. 2009 Sep;93(9):1159-62
pubmed: 19704040
Pediatr Blood Cancer. 2014 Aug;61(8):1440-4
pubmed: 24402721
J Natl Cancer Inst. 2007 Jan 3;99(1):24-31
pubmed: 17202110
Br J Cancer. 2014 May 13;110(10):2623-32
pubmed: 24755883
Fam Cancer. 2012 Jun;11(2):225-33
pubmed: 22205104
Ophthalmology. 2001 Oct;108(10):1868-76
pubmed: 11581064
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1464-8
pubmed: 16896033
Ophthalmic Genet. 2001 Jun;22(2):77-88
pubmed: 11449317
Br J Cancer. 2013 Jun 25;108(12):2455-63
pubmed: 23674091
CA Cancer J Clin. 2016 Mar-Apr;66(2):96-114
pubmed: 26797525
Pediatr Blood Cancer. 2016 Sep;63(9):1608-14
pubmed: 27195454
Ophthalmic Genet. 1997 Mar;18(1):27-34
pubmed: 9134547
Ophthalmology. 1988 Nov;95(11):1583-7
pubmed: 3211467
JAMA Oncol. 2017 Dec 1;3(12):1634-1639
pubmed: 28772291
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
Radiat Res. 2005 Jun;163(6):701-2
pubmed: 16044502
Med Pediatr Oncol. 1998 Jan;30(1):59-62
pubmed: 9371391
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 May-Jun;81(3 Pt 1):454-7
pubmed: 1066869
Ophthalmology. 1998 Apr;105(4):573-9; discussion 579-80
pubmed: 9544627
AJR Am J Roentgenol. 2015 Aug;205(2):400-8
pubmed: 26204294
Doc Ophthalmol. 1997;93(4):337-44
pubmed: 9665291
J Clin Oncol. 2004 Dec 15;22(24):4979-90
pubmed: 15576413
J Clin Oncol. 2005 Apr 1;23(10):2272-9
pubmed: 15800318
Ophthalmology. 2001 Jun;108(6):1109-14
pubmed: 11382638
Pediatr Blood Cancer. 2013 Apr;60(4):543-9
pubmed: 23281199
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Jpn J Clin Oncol. 2011 Mar;41(3):373-9
pubmed: 21051531
J Natl Compr Canc Netw. 2018 Aug;16(8):939-949
pubmed: 30099370
Am J Ophthalmol. 2015 Nov;160(5):953-8
pubmed: 26255575
Clin Cancer Res. 2017 Jul 1;23(13):e98-e106
pubmed: 28674118
Eur J Cancer. 2004 Jul;40(10):1522-9
pubmed: 15196536
Int J Cancer. 1988 Apr 15;41(4):499-504
pubmed: 3356485
J Natl Cancer Inst. 2000 Dec 20;92(24):2037-9
pubmed: 11121467
BMC Cancer. 2018 Sep 27;18(1):932
pubmed: 30261866
Gynecol Oncol. 2012 Feb;124(2):254-9
pubmed: 22027510
J Natl Cancer Inst. 1993 Jul 21;85(14):1121-8
pubmed: 8320741
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9
pubmed: 19066271
Lancet Oncol. 2016 Sep;17(9):1295-305
pubmed: 27501770
Lancet Neurol. 2017 Jul;16(7):564-570
pubmed: 28653648
J Paediatr Child Health. 2019 Apr;55(4):459-464
pubmed: 30251373
J Clin Oncol. 2017 May 10;35(14):1570-1576
pubmed: 28339329
J Clin Oncol. 2014 Oct 10;32(29):3284-90
pubmed: 25185089
Int J Cancer. 2008 Nov 1;123(9):2156-63
pubmed: 18712734
Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):257-66
pubmed: 22078749
JAMA. 2016 Jul 26;316(4):436-47
pubmed: 27458949
Pediatr Blood Cancer. 2014 Jan;61(1):116-9
pubmed: 23918737
J Natl Cancer Inst. 2004 Mar 3;96(5):357-63
pubmed: 14996857
Br J Ophthalmol. 2019 Sep;103(9):1272-1277
pubmed: 30361279
Radiat Res. 1990 Jul;123(1):87-92
pubmed: 2371384
Rev Esp Enferm Dig. 2015 Sep;107(9):584-5
pubmed: 26334473
Arch Ophthalmol. 2010 Jul;128(7):865-70
pubmed: 20625047
JAMA. 2011 Jun 8;305(22):2311-9
pubmed: 21642683
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):528-32
pubmed: 23549396
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
Clin Sarcoma Res. 2012 Oct 04;2(1):15
pubmed: 23036192
Eur J Cancer. 2006 Sep;42(13):2092-102
pubmed: 16919773
Eur J Cancer. 2009 Dec;45(18):3245-53
pubmed: 19493675
Lancet Oncol. 2013 Jul;14(8):e321-8
pubmed: 23816298
Clin J Gastroenterol. 2015 Aug;8(4):217-22
pubmed: 26208828
J Clin Oncol. 2018 Jul 20;36(21):2145-2152
pubmed: 29874133
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):863-9
pubmed: 25227498
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954302
J Clin Oncol. 2012 Mar 20;30(9):950-7
pubmed: 22355046
Genome Med. 2011 Aug 23;3(8):52
pubmed: 21861849
JAMA Oncol. 2017 Dec 1;3(12):1640-1645
pubmed: 28772286
J Pediatr. 1983 Jul;103(1):65-9
pubmed: 6864397
J Clin Oncol. 2019 Aug 20;37(24):2131-2140
pubmed: 31260642
Am J Ophthalmol. 1998 Aug;126(2):269-77
pubmed: 9727521
Pediatr Blood Cancer. 2017 Jan;64(1):71-80
pubmed: 27567086
BMC Health Serv Res. 2018 Sep 27;18(1):740
pubmed: 30261925
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74
pubmed: 16054775
Oncogene. 2006 Aug 28;25(38):5350-7
pubmed: 16936757
Am J Clin Oncol. 2004 Aug;27(4):411-9
pubmed: 15289737